Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
May 26, 2022 17:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
May 11, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers

Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancersStarting dose of 1 mg/kg expected to reduce time and cost...
May 10, 2022 16:30 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports First Quarter 2022 Financial Results

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
March 10, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively...
March 02, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to...
February 15, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting

Presentation provides mechanistic insights and progress update on collaboration with the laboratory of Michael Dustin at the University of Oxford to study the role of IL-2 in the T cell immunological...
January 26, 2022 16:01 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in the 2mg/kg and RP2D 4mg/kg cohorts, two have...
January 20, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
January 05, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102

Selective activation and expansion of Wilms’ Tumor 1 (WT1)-specific cytotoxic CD8+ T cells in preclinical models supports the potential for clinical activity treating WT1-expressing cancersFurther...